---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical presentation - signs and symptoms. Topics: Wheals: definition in the 2026 international guideline, Angioedema: definition in the 2026 international guideline, Angioedema frequency and symptoms: 673 adults with inadequately controlled CSU, Angioedema reporting in medical records and patient reports: 673 participants, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Wheals: definition in the 2026 international guideline

> “Urticaria is a condition characterized by the development of wheals (hives), angioedema or both. A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.6-2"></a>

### Angioedema: definition in the 2026 international guideline

> “Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.6-3"></a>

### Angioedema frequency and symptoms: 673 adults with inadequately controlled CSU

> “According to medical records, 58.5% (394 of 673) patients were reported to have had CSU‐associated angioedema, and 41.0% (276 of 673) had experienced CSU‐associated angioedema within the past 12 months from inclusion.”
> “According to the patient survey, 65.8% of patients (427 of 649) reported experiencing angioedema during the previous 12 months; of these, 75.2% (321 of 427) reported having experienced angioedema within the past 4 weeks.”
> “Patients with angioedema reported on a scale of 0‐10 the amount of itching (mean [SD] 7.2 [2.16]), swelling (7.3 [2.73]), and pain (5.4 [3.39]) they experienced during a typical episode over the past 12 months.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.6-4"></a>

### Angioedema reporting in medical records and patient reports: 673 participants

> “This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria”
> “Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema , No‐angioedema and Misaligned category, respectively.”

Source: [Sussman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055840/)

<a id="topic-2.2.1.6-5"></a>

### Angioedema in the past 3 months: physician-diagnosed CSU in a 2019 United States survey

> “Approximately half (49.1%) of the respondents reported experiencing angioedema in the past 3 months, with the mean (SD) number of angioedema events in the past 3 months being 3.9 (5.7).”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.6-6"></a>

### Itch: pruritus as a key symptom and its effect on daily life and work

> “It captures the two key signs and symptoms of urticaria—wheals and pruritus—based on daily self‐assessments by the patient”
> “Its debilitating symptoms—severe pruritus and wheals—disruption of daily activities, sleep, and emotional well‐being can create a cycle of frustration and decreased quality of life (QoL) often worsened by comorbidities such as anxiety and depression”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “The main reasons affecting capacity to work were itching (39.8%) and angioedema (28.2%).”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.6-7"></a>

### Sleep: interference with sleep and claims for sleep-related conditions

> “Chronic spontaneous urticaria markedly interfered with sleep and daily activities.”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

> “Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).”
> “Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%)”
> “a higher proportion of patients with uncontrolled vs controlled disease had ≥1 claim for sleep-related (17.3% and 13.4%) and MH conditions (60.6% and 51.9%).”

Source: [Riedl et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43003384/)

Additional sources: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
